SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

Search

Vetoquinol SA

Fermé

SecteurSoins de santé

79.8 1.53

Résumé

Variation du prix de l'action

24h

Actuel

Min

79.6

Max

79.8

Chiffres clés

By Trading Economics

Revenu

25M

Ventes

10M

268M

P/E

Moyenne du Secteur

15.686

63.808

Rendement du dividende

1.17

Marge bénéficiaire

9.734

Employés

2,497

EBITDA

252M

301M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+37.5% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.17%

2.38%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

12M

947M

Ouverture précédente

78.27

Clôture précédente

79.8

Sentiment de l'Actualité

By Acuity

50%

50%

150 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Vetoquinol SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 avr. 2026, 20:26 UTC

Acquisitions, Fusions, Rachats

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 avr. 2026, 18:15 UTC

Principaux Événements d'Actualité

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 avr. 2026, 16:49 UTC

Principaux Événements d'Actualité

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

18 avr. 2026, 01:00 UTC

Principaux Événements d'Actualité

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 avr. 2026, 22:58 UTC

Résultats

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 avr. 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 avr. 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 avr. 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 avr. 2026, 20:52 UTC

Résultats

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 avr. 2026, 20:50 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

17 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 avr. 2026, 20:29 UTC

Résultats

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 avr. 2026, 20:11 UTC

Acquisitions, Fusions, Rachats

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 avr. 2026, 19:34 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

17 avr. 2026, 19:34 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 avr. 2026, 19:31 UTC

Market Talk
Principaux Événements d'Actualité

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 avr. 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17 avr. 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 avr. 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 avr. 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 avr. 2026, 18:57 UTC

Principaux Événements d'Actualité

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 avr. 2026, 18:53 UTC

Acquisitions, Fusions, Rachats

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 avr. 2026, 18:53 UTC

Acquisitions, Fusions, Rachats

UCB 2026 Rev Guidance Unchanged

17 avr. 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 avr. 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 avr. 2026, 18:14 UTC

Market Talk
Principaux Événements d'Actualité

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 avr. 2026, 18:00 UTC

Principaux Événements d'Actualité

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 avr. 2026, 18:00 UTC

Principaux Événements d'Actualité

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 avr. 2026, 17:31 UTC

Market Talk
Principaux Événements d'Actualité

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 avr. 2026, 17:26 UTC

Market Talk
Résultats

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparaison

Variation de prix

Vetoquinol SA prévision

Objectif de Prix

By TipRanks

37.5% hausse

Prévisions sur 12 Mois

Moyen 110 EUR  37.5%

Haut 110 EUR

Bas 110 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

72.6 / 75.1Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

150 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat